Invivyd (IVVD) said Monday virology data supports its assertion its half-life extended investigational monoclonal antibody PEMGARDA, or pemivibart, is effective against current SARS-CoV-2 variant spike proteins.
Invivyd collaborates with LabCorp's Monogram Biosciences to monitor antiviral activity for independent virology assessments, and to deterime if its pemivibart potency needs to be changed as SARS-CoV-2 variants evolve.
Shares of the company were up 2.5% in recent Monday premarket activity.
Price: 1.2300, Change: +0.03, Percent Change: +2.50
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。